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Because of its geographical location at the 
southernmost extent of malaria distribution, 
historically South Africa (SA) was spared much 
of the devastation caused by malaria in the rest of 
Africa. Nevertheless, seasonal malaria epidemics 
caused many deaths until the advent of effective vector control 
methods and antimalarial drugs in the 1930s and 1940s. The 
country has recently managed to turn the tide on this disease by 
implementing practical, evidence-based, World Health Organization 
(WHO)-recommended interventions. Today the programme has 
moved beyond malaria control and is on a trajectory for malaria 
elimination (defined as zero local malaria cases in a defined 
geographical area).[1] In this article we document the successes and 
challenges that SA has experienced in malaria control and highlight 
priorities for elimination of the disease. 
There were ~219 million cases of malaria in 2010 and an estimated 
660 000 deaths globally, with Africa being the most affected continent, 
contributing ~90% of all malaria deaths.[2] Several declarations 
committing to reducing the burden of malaria have been signed 
by African heads of state and ministers. The Abuja Declaration 
was signed on 25 April 2000 by leaders from 44 malaria-endemic 
countries, in which they committed to an intensive effort to halve 
malaria mortality for African people by 2010, from the baseline of the 
year 2000.[3] The Millennium Development Goals (MDGs), adopted 
in 2001, comprise the key goals of alleviating poverty and disease 
and improving human development. Various governments and non-
governmental and multilateral agencies use the MDGs (eight in total) 
as a universal yardstick to monitor individual country progress on 
health performance. Goal 6 of the MDGs was set to combat HIV/
AIDS, malaria and other diseases and has the target of halting these 
diseases by 2015 and beginning to reverse the incidence of malaria 
and other infectious diseases.[4] 
It is important to gauge the progress that SA has made with regard to 
these declarations. Between 2000 and 2012, SA reduced the burden of 
malaria by ~90% (64 622 v. 6 846 cases, respectively) and mortality by 
~80% (459 v. 91 deaths, respectively) (Fig. 1). SA has achieved Abuja 
and MDG targets and is now well poised to pursue a programme of 
malaria elimination. 
At the African Union Conference of Ministers of Health in 
2007, member states launched the Africa Malaria Elimination 
Campaign, committing to transition eligible countries from malaria 
control to malaria elimination.[5] Later that year, the Southern 
African Development Community (SADC) similarly pledged to 
eliminate malaria from southern Africa. The SADC Malaria Strategic 
Framework and a subsequent Malaria Elimination Framework urged 
member states to identify potential areas for elimination and to 
develop national malaria elimination strategic plans. Encouraged 
by the promise that a co-ordinated regional approach holds for 
malaria elimination in southern Africa, a concept of the Malaria 
Elimination 8 was agreed to by SADC member states, committing 
six countries – Botswana, Namibia, SA and Swaziland, as well as the 
island states of Zanzibar and Madagascar – to eliminate malaria by 
2015.[6] It is clear that malaria does not respect national borders, and 
sustainable elimination in SA will require regional involvement. The 
Lubombo Spatial Development Initiative (LSDI) has shown what 
can be achieved by regional co-operation, particularly with regard 
to Swaziland and KwaZulu-Natal and Mpumalanga provinces. The 
LSDI started in 1999 as a large-scale project and was initiated in 
northern KwaZulu-Natal, Mpumalanga, southern Mozambique and 
Swaziland. It is aimed at accelerating development, particularly with 
regard to tourism, within an area of ~100 000  km2.[7] Subsequent 
to the robust implementation of an indoor residual spraying (IRS) 
programme, coupled with definitive diagnosis and treatment with 
artemesinin-based combination treatments (ACTs), the incidence 
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of malaria has declined in SA (KwaZulu-
Natal and Mpumalanga provinces) and 
Swaziland (Lubombo) by 99% compared 
with the 2000 baseline. In KwaZulu-Natal 
and Mpumalanga provinces, malaria 
incidence decreased by 99% (from ~42 400 
to 550 cases) and 72% (from ~12 000 to 
3 350 cases), respectively, between the 
1999/2000 and 2010/2011 malaria seasons. 
The prevalence of the disease had decreased 
by 92% in southern Mozambique up to 2009 
(Fig. 2).[8] 
Unfortunately, international funding for 
the LSDI has dried up and it is likely that 
some of the gains achieved in Mozambique 
will not be sustained. Notwithstanding this, 
SA is embarking on a campaign to eliminate 
the disease within its borders by 2018.[9] 
From control to 
elimination: The key 
elements
For SA to stay on target for eliminating 
malaria, the following are essential:[9]
• active surveillance in response to confirmed 
cases and treatment of identified cases, to 
interrupt local transmission
• utilising sensitive diagnostic tests to detect 
low-level parasitaemia
• maintaining a high level of malaria 
awareness in communities and health 
workers, as the malaria prevalence decreases
• monitoring parasite drug and vector 
resistance, as these risks increase when 
malaria case numbers decrease 
• supporting malaria control measures in 
neighbouring countries more effectively 
• sustaining continued resourcing in the 
face of reduced case numbers.
Malaria vector control
In a malaria vector control programme, 
accurate identification by modern molecular 
methods of the mosquitoes involved in 
transmission of the disease is essential. 
Mosquitoes are incriminated in malaria 
transmission by detecting Plasmodium 
sporozoites or circumsporozoite protein in 
identified females with immunological and 
Fig. 2. Reduction in malaria prevalence between 2000 and 2010, Lubombo Spatial Development Initiative.[8]
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Fig 1. Malaria cases and deaths, South Africa, 2000 - 2012.
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molecular assays. In SA, in general, Anopheles funestus is usually 
associated with outbreaks and epidemics, while A. arabiensis is 
considered largely responsible for comparatively low-level seasonal 
transmission in malaria-affected regions.[10] Malaria vector control 
is insecticide based, relying primarily on IRS. This intervention 
has generally proved effective where appropriately implemented. [11,12] 
However, insecticide resistance in target vector populations can 
undermine the effectiveness of IRS and long-lasting insecticide-treated 
bed nets.[13-16] Resistance to insecticides in SA malaria vector populations 
is a relatively recent occurrence. In 1999 - 2000, a malaria epidemic in 
KwaZulu-Natal Province erupted because pyrethroid resistance caused 
failure of IRS, and led to the re-introduction of dichloro-diohenyl-
trichloroethane (DDT) for this purpose, under an exemption from 
the UN Stockholm Convention on Persistent Organic Pollutants, 
through which DDT had been banned worldwide except for public 
health use. Together with a treatment policy shift, this change brought 
the malaria epidemic under control. Insecticide resistance in target 
vector populations coupled with environmental and health concerns 
associated with insecticide use has led to a burgeoning interest in 
the development of alternative forms of vector control[17] as well as 
to implementation of integrated vector management strategies. [18,19] 
Entomological surveillance is a fundamentally important activity in a 
malaria vector control programme, for several reasons, and operational 
research and specialised diagnostics arise from activities such as 
species identification using morphological and molecular methods, 
vector incrimination using immunological methods, and insecticide 
susceptibility testing. 
Case management: Diagnosis
Accurate diagnosis of malaria is important for the individual patient 
as well as for control programmes. Microscopic examination of 
Giemsa-stained blood films is still the operational gold standard 
for the diagnosis of clinical malaria, but microscope quality 
and maintenance, and staining quality and technique, are often 
suboptimal, especially in remote, poorly resourced settings.[20] The 
malaria rapid diagnostic test (RDT) is relatively simple to perform, 
and allows for point-of-care diagnosis and hence immediate malaria 
treatment.[21,22] The SA National Department of Health became the 
first African health ministry to implement a definitive malaria 
diagnosis policy using RDTs at all public sector health facilities in 
1996.[23] Although RDTs have proved to be extremely cost-effective in 
sub-Saharan Africa,[24] their usefulness on the continent is sometimes 
constrained by sensitivity and specificity issues, as well as user-related 
problems. Typical parasite loads in geographical areas targeted for 
malaria elimination are expected to fall well below 100 parasites/μl 
in blood, the approximate design detection limit of RDTs, fuelling 
calls for the development and use of more sensitive nucleic acid-
based techniques.[25] Microscopy and RDTs, when performed and 
interpreted optimally, are suitable for case management, and in the 
local context attention will need to be paid to quality improvement, 
maintenance and support. As SA embarks on its elimination agenda, 
mass screening and treating sufficient numbers of potential malaria 
carriers, whether symptomatic or asymptomatic, to interrupt malaria 
transmission becomes imperative.[26] Detecting and eradicating 
every parasite, both asexual parasites and gametocytes, using 
methods sensitive to low-density infections such as nucleic acid-
based technologies, is therefore essential.[25,27] Efficient surveillance 
of parasite drug resistance by in vitro, in vivo, and/or molecular 
methods will be essential to inform treatment policy. 
Case management: Treatment
South Africans living in malaria transmission areas are generally non-
immune and all age groups are at risk of developing severe malaria.[28,29] 
Prompt treatment with effective drugs is the key to reducing malaria 
morbidity and mortality.[1,30,31] Evidence-based guidelines have dictated 
the selection of antimalarials in the SA malaria control programme, 
and have also considered the impact on transmission and antimalarial 
drug resistance issues. 
Before the advent of chloroquine (CQ) in the late 1940s, quinine 
was used for both treatment and prophylaxis. During the 1970s, 
the focus was on malaria case detection and CQ treatment, mainly 
through active case finding during house-to-house surveys and mass 
blood examination. In the mid-1990s, the District Health System, 
based on primary healthcare, was adopted as the healthcare strategy 
for SA.[32] Passive detection and prompt, effective treatment of malaria 
at primary healthcare facilities, based on parasitological diagnosis 
with RDTs, became the policy for case management.[33,34]
The emergence of CQ resistance in KwaZulu-Natal necessitated 
a change to sulphadoxine-pyrimethamine (SP) in 1988, and then to 
artemether-lumefantrine (AL) in 2001, following treatment failures 
and identification of molecular resistance markers for SP. Treatment 
policy changes in Limpopo and Mpumalanga provinces were based 
on rigorous drug resistance monitoring and early identification of 
predictive molecular resistance markers for SP resistance (Table 1).[35]
AL is the current first-line antimalarial for the treatment of 
uncomplicated falciparum malaria. Second-line antimalarials for 
uncomplicated malaria remain oral quinine, plus doxycycline (for 
adults) or clindamycin (for pregnant women and children <8 years). [29] 
Parenteral quinine is the mainstay of treatment of severe malaria. [36,37] 
Intravenous artesunate is currently recommended by the WHO for 
severe malaria in adults and children, with an increased survival 
advantage and fewer adverse reactions than quinine.[30,38] Intravenous 
artesunate is not yet registered for use in SA, but there is limited 
availability through a special access programme.[29]
The number of malaria-related deaths is a key epidemiological 
indicator to evaluate performance in delivering effective malaria case 
management.[30] Late presentation, lack of awareness of malaria in 
communities, and a low index of suspicion on the part of healthcare 
workers, particularly in non-endemic provinces in the country,[39-42] 
are major factors contributing to malaria-related deaths. Even in 
the endemic provinces, case fatality rates (number of deaths per 100 
cases of malaria) are above the national target of <0.5%. Continuing 
education of healthcare workers on malaria diagnosis and treatment 
is of critical importance.[43]
The emergence of drug resistance in areas of low transmission 
intensity is the biggest threat to treatment. With artemisinin resistance 
already confirmed in the Greater Mekong Region of Southeast 
Asia, and no molecular marker for detecting artemisinin-resistant 
parasites, there is a real possibility of this resistance spreading to, or 
emerging in, SA. Conducting in vivo drug efficacy trials in regions 
approaching malaria elimination is virtually impossible owing to 
low case numbers. Until validated molecular markers are available 
Table 1. Year in which first-line malaria treatment policy was 
changed in South Africa, by province[35]
Province CQ SP
Artesunate-
SP AL
KwaZulu-Natal 1940s 1988 - 2001
Mpumalanga 1940s 1997 2001 2006
Limpopo 1940s 1998 - 2004
CQ = Chloroquine; SP = sulphadoxine-pyrimethamine; AL = artemether-lumefantrine.
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for artemisinin resistance, our best options are routine monitoring 
for molecular markers of resistance to lumefantrine (or future ACT 
partner drugs), and whenever possible to test for P. falciparum 
parasites 3 days after treatment, and to follow up patients 4 - 6 weeks 
after treatment to establish whether they remain malaria free.[44]
Interrupting the cycle of malaria transmission in the community is 
a key strategy in the continuum from control to elimination. Active 
case surveillance using sensitive molecular techniques, the use of 
gametocytocidal drugs such as primaquine,[45] and community-
based treatment of asymptomatic malaria all need to be considered. 
Before the elimination programme decides to go ahead with routine 
primaquine use, it needs to update local knowledge about glucose-6-
phosphate dehydrogenase deficiency in SA, for ethical and scientific 
reasons.[46]
Conclusions
SA has achieved remarkable success in controlling malaria over the 
past century, and particularly in the past decade. Epidemiologically 
the incidence of malaria in SA places the country in the pre-
elimination category, namely <5 malaria cases per 1 000 population 
at risk, and in some municipalities at the elimination stage of <1 
case per 1  000 population at risk.[1] However the success of SA’s 
malaria elimination programme will depend on early detection 
of malaria cases, with rapid appropriate treatment and vector 
control response to foci of transmission, maintaining a high level of 
vector control coverage, especially in the high-transmission areas, 
ensuring that drugs, insecticides and diagnostic tools are of the 
highest quality, ensuring that cross-border malaria initiatives are 
ongoing, monitoring insecticide and drug resistance, and sustaining 
partnerships in advocating for continued resourcing for malaria 
control and elimination.
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